Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020

Table of Contents

Chapter 1.   Executive Summary

                1.1.  Antidiabetics - Industry Summary and Critical Success Factors (CSFs)

Chapter 2.   Antidiabetics Industry Outlook

                2.1.  Market Segmentation

                2.2.  Market size and growth prospects

                2.3.  Antidiabetics - Market dynamics

                    2.3.1.  Market driver analysis

                        2.3.1.1  Growing prevalence of diabetes

                        2.3.1.2  Presence of a strong product pipeline portfolio

                        2.3.1.3  Growing prevalence of lifestyle-induced disorders such as obesity

                    2.3.2.  Market Restraint Analysis

                        2.3.2.1.  High insulin prices

                2.4.  Key Opportunities Prioritized

                2.5.  Industry Analysis - Porter’s

                2.6.  Antidiabetics - PESTEL analysis

                2.7.  Antidiabetics Market - Pipeline overview

Chapter 3.   Antidiabetics Product Outlook

                3.1.  Antidiabetics market share by product, 2013 & 2020

                3.2.  Insulin

                    3.2.1.  Insulin market share, by product, 2013 & 2020

                    3.2.2.  Rapid-acting analog market

                        3.2.2.1.  Rapid-acting analog market, 2012 - 2020 (USD Million)

                    3.2.3.  Long-acting analog market

                        3.2.3.1  Long-acting analog market, 2012 - 2020 (USD Million)

                    3.2.4.  Premixed analog market

                        3.2.4.1  Premixed analog market, 2012 - 2020 (USD Million)

                    3.2.5.  Premixed insulin market

                        3.2.5.1.  Premixed insulin market, 2012 - 2020 (USD Million)

                    3.2.6.    Short-acting insulin market

                        3.2.6.1.  Short-acting insulin market, 2012 - 2020 (USD Million)

                    3.2.7.  Intermediate-acting insulin market

                        3.2.7.1  Intermediate-acting insulin market, 2012 - 2020 (USD Million)

                3.3.  Other antidiabetics

                3.4.  Alpha-glucosidase inhibitors

                    3.4.1.  Alpha-glucosidase inhibitors market, 2012 - 2020 (USD Million)

                3.5.  Biguanides

                    3.5.1.  Biguanides market, 2012 - 2020 (USD Million)

                3.6.  Sulphonylureas

                    3.6.1.  Sulphonylureas market, 2012 - 2020 (USD Million)

                3.7.  GLP 1 (Glucagon-like peptide) agonists

                    3.7.1.  GLP 1 agonist market, 2012 - 2020 (USD Million)

                3.8.  DPP - 4 (Dipeptidyl peptides) inhibitors

                    3.8.1.  DPP-4 market, 2012 - 2020 (USD Million)

                3.9.  Meglitinides

                    3.9.1.  Meglitinides market, 2012 - 2020 (USD Million)

                3.10.  SGLT - 2 (sodium-glucose transport proteins) inhibitors

                    3.10.1.  SGLT - 2 inhibitors market, 2012 - 2020 (USD Million)

                3.11.  Thiazolidinediones

                    3.11.1.  Thiazolidinediones market, 2012 - 2020 (USD Million)

Chapter 4.   Antidiabetics Regional Outlook

                4.1.  Antidiabetics market share, by region, 2013 & 2020

                4.2.  North America antidiabetics market

                    4.2.1.  North America antidiabetics market, 2012 - 2020 (USD Million)

                4.3.  Europe antidiabetics market

                    4.3.1.  Europe antidiabetics market, 2012 - 2020 (USD Million)

                4.4.  Asia Pacific antidiabetics market

                    4.4.1.  Asia Pacific antidiabetics Market, 2012 - 2020 (USD Million)

                4.5.  RoW antidiabetics market

                    4.5.1.  RoW antidiabetics market, 2012 - 2020 (USD Million)

Chapter 5.   Competitive Landscape

                5.1 Sanofi Aventis

                    5.1.1 Company Overview

                    5.1.2 Financial Performance

                    5.1.3 Product Benchmarking

                    5.1.4 Strategic Initiatives

                5.2 Takeda Pharmaceuticals

                    5.2.1 Company Overview

                    5.2.2 Financial Performance

                    5.2.3 Product Benchmarking

                    5.2.4 Strategic Initiatives

                5.3 Eli Lilly

                    5.3.1 Company Overview

                    5.3.2 Financial Performance

                    5.3.3 Product Benchmarking

                    5.3.4 Strategic Initiatives

                5.4 Oramed Pharmaceuticals Inc.

                    5.4.1 Company Overview

                    5.4.2 Financial Performance

                    5.4.3 Product Benchmarking

                    5.4.4 Strategic Initiatives

                5.5 Merck & Co. Inc.

                    5.5.1 Company Overview

                    5.5.2 Financial Performance

                    5.5.3 Product Benchmarking

                    5.5.4 Strategic Initiatives

                5.6 Novo Nordisk

                    5.6.1 Company Overview

                    5.6.2 Financial Performance

                    5.6.3 Product Benchmarking

                    5.6.4 Strategic Initiatives

                5.7 Bristol-Myers Squibb

                    5.7.1 Company Overview

                    5.7.2 Financial Performance

                    5.7.3 Product Benchmarking

                    5.7.4 Strategic Initiatives

                5.8 Halozyme Therapeutics

                    5.8.1 Company Overview

                    5.8.2 Financial Performance

                    5.8.3 Product Benchmarking

                    5.8.4 Strategic Initiatives

                5.9 Pfizer

                    5.9.1 Company Overview

                    5.9.2 Financial Performance

                    5.9.3 Product Benchmarking

                    5.9.4 Strategic Initiatives

Chapter 6.   Methodology and Scope

                6.1.  Research Methodology

                6.2.  Research Scope & Assumptions

                6.3.  List of Data Sources

List of Tables

1. Antidiabetics - Industry Summary & Critical Success Factors (CSFs)
2. Global insulin market, by product, 2012 - 2020 (USD Million)
3. Global other antidiabetics market, by product, 2012 - 2020 (USD Million)
4. Global antidiabetics market, by region, 2012 - 2020 (USD Million)
5. Antidiabetics - Key market driver analysis
6. North America diabetes prevalence (national prevalence %), 2013 & 2035
7. Europe diabetes prevalence (national prevalence %), 2013 & 2035
8. Latin America diabetes prevalence (national prevalence %), 2013 & 2035
9. MENA and Africa diabetes prevalence (national prevalence %), 2013 & 2035
10. CIS diabetes prevalence (national prevalence %), 2013 & 2035
11. Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035
12. Antidiabetics - Key market restraint analysis
13. Antidiabetics Market - Pipeline overview
14. Insulin types and brands
15. List of brands of alpha-glucosidase for diabetes
16. List of major brands of biguanides for diabetes
17. Brands and generic names of sulphonylureas for diabetes
18. Brands and generic names of GLP-1 for diabetes
19. List of major brands of DPP-4 for diabetes
20. List of major drugs of meglitinides for diabetes
21. List of major drugs of SGLT-2 for diabetes
22. North America insulin market, by product, 2012 - 2020 (USD Million)
23. North America insulin market, by application, 2012 - 2020 (USD Million)
24. North America other antidiabetics market, by product, 2012 - 2020 (USD Million)
25. Europe insulin market, by product, 2012 - 2020 (USD Million)
26. Europe insulin market, by application, 2012 - 2020 (USD Million)
27. Europe other antidiabetics market, by product, 2012 - 2020 (USD Million)
28. Asia Pacific insulin market, by product, 2012 - 2020 (USD Million)
29. Asia Pacific insulin market, by application, 2012 - 2020 (USD Million)
30. Asia pacific other antidiabetics market, by product, 2012 - 2020 (USD Million)
31. RoW insulin market, by product, 2012 - 2020 (USD Million)
32. RoW insulin market, by application, 2012 - 2020 (USD Million)
33. RoW other antidiabetics market, by product, 2012 - 2020 (USD Million)

List of Figures

1. Antidiabetics market segmentation
2. Global antidiabetics market revenue, 2012 - 2020 (USD Million)
3. Antidiabetics: Market dynamics
4. Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million)
5. Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)
6. Key opportunities prioritized
7. Antidiabetics market - Porter’s analysis
8. Antidiabetics market - PESTEL analysis
9. Antidiabetics market share by product, 2013 & 2020
10. Insulin market share by product, 2013 & 2020
11. Rapid-acting analog market, 2012 - 2020 (USD Million)
12. Long-acting analog market, 2012 - 2020 (USD Million)
13. Premixed analog market, 2012 - 2020 (USD Million)
14. Premixed insulin market, 2012 - 2020 (USD Million)
15. Short-acting insulin market, 2012 - 2020 (USD Million)
16. Intermediate-acting insulin market, 2012 - 2020 (USD Million)
17. Global alpha-glucosidase inhibitors market, 2012 - 2020 (USD Million)
18. Global biguanides market, 2012 - 2020 (USD Million)
19. Global sulphonylureas market, 2012 - 2020 (USD Million)
20. Global GLP 1 agonist market, 2012 - 2020 (USD Million)
21. Global DPP-4 market, 2012 - 2020 (USD Million)
22. Global meglitinides market, 2012 - 2020 (USD Million)
23. Global SGLT - 2 inhibitors market, 2012 - 2020 (USD Million)
24. Global thiazolidinediones market, 2012 - 2020 (USD Million)
25. Antidiabetics market share by region, 2013 & 2020
26. North America antidiabetics market, 2012 - 2020 (USD Million)
27. Europe antidiabetics market, 2012 - 2020 (USD Million)
28. Asia Pacific antidiabetics market, 2012 - 2020 (USD Million)
29. RoW antidiabetics market, 2012 - 2020 (USD Million)